4DMedical Ltd (AU:4DX) has released an update.
4DMedical Limited has issued 19 million shares to Alpha Investment Partners as collateral for a recently announced ATM facility, utilizing its existing capacity under the ASX Listing Rules. The issue falls within an exemption to allow on-sale without disclosure, and the company confirms compliance with relevant provisions of the Corporations Act 2001. Additionally, 4DMedical, known for its patented XV Technology® that enhances lung function analysis, recently acquired Imbio, a company specializing in AI imaging solutions for lung and cardiothoracic diseases.
For further insights into AU:4DX stock, check out TipRanks’ Stock Analysis page.